source
- Merck's anti-TL1A antibody shows benefit in hidradenitis suppurativa but misses endpoint in rare lung disease trialMerck reported mixed results from its anti‑TL1A antibody, a product of its $10.8 billion acquisition of Prometheus Biosciences. In a mid‑stage study for hidradenitis suppurativa, the antibody met…
- AstraZeneca and Bristol Myers Squibb rumored to be in talks for a major mergerOver the weekend, reports emerged that AstraZeneca and Bristol Myers Squibb were reportedly discussing a possible merger. Industry observers note that such a combination would create one of the la…